home / stock / aadi / aadi news

AADI News and Press, Aadi Bioscience Inc. From 11/15/21

Stock Information
Company Name: Aadi Bioscience Inc.
Stock Symbol: AADI
Market: NASDAQ
Website: aadibio.com
Menu
AADI AADI Quote AADI Short AADI News AADI Articles AADI Message Board
Get AADI Alerts

News, Short Squeeze, Breakout and More Instantly...
AADI - UPDATE - Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)

In an Expanded Access Program, advanced malignant PEComa patients who previously progressed on other mTOR inhibitors showed a 25% partial response rate and 63% clinical benefit rate when treated with nab-sirolimus; the subset of patients with TSC1 or TSC2 alterations showed a 44% re...
AADI - Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)

In an Expanded Access Program, advanced malignant PEComa patients who previously progressed on other mTOR inhibitors showed a 25% partial response rate and 63% clinical benefit rate when treated with nab-sirolimus In a final analysis from the AMPECT registrational t...

AADI - Aadi Bioscience reports Q3 results

Aadi Bioscience (NASDAQ:AADI): Q3 GAAP EPS of -$9.17. Cash and cash equivalents of $161.37M Press Release For further details see: Aadi Bioscience reports Q3 results

AADI - Aadi Reports Third Quarter 2021 Financial Results and Provides Business Update

FYARRO™ under review with FDA with a November 26, 2021 PDUFA target date Three key executive appointments made to the roles of Chief Operating Officer, Chief Medical Officer and Chief Financial Officer Appointment of new board member Registrational trial i...
AADI - Aadi Bioscience to Participate in Upcoming Investor Conferences

LOS ANGELES, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”), clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that management will be participating...

AADI - Aadi Bioscience rises on CFO appointment

Aadi Bioscience (NASDAQ:AADI) has appointed Scott Giacobello as Chief Financial Officer (CFO) and Treasurer, effective November 28, 2021. Giacobello previously served as CFO of GW Pharmaceuticals. AADI +1.46% AH For further details see: Aadi Bioscience rises on CFO appointment...

AADI - Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer

LOS ANGELES, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of S...
AADI - Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer

LOS ANGELES, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of L...

AADI - Aadi Bioscience Announces Publication of its Phase 2 Registrational (AMPECT) Trial of nab-Sirolimus in Patients with Malignant Perivascular Epithelioid Cell Tumors in the Journal of Clinical Oncology

LOS ANGELES, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the publication of &...

AADI - Aadi Bioscience to Participate in H.C. Wainwright's 2nd Annual Precision Oncology Conference 2021

LOS ANGELES, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”), a privately-held clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief ...
Previous 10 Next 10